Adult humans have about 25 trillion red blood cells (RBCs), and each second we recycle about 5 million RBCs by erythrophagocytosis (EP) in macrophages of the reticuloendothelial system. Despite the central role for EP in mammalian iron metabolism, the molecules and pathways responsible for heme trafficking during EP remain unknown. Here, we show that the mammalian homolog of HRG1, a transmembrane heme permease in C. elegans, is essential for macrophage iron homeostasis and transports heme from the phagolysosome to the cytoplasm during EP. HRG1 is strongly expressed in macrophages of the reticuloendothelial system and specifically localizes to the phagolysosomal membranes during EP. Depletion of Hrg1 in mouse macrophages causes attenuation of heme transport from the phagolysosomal compartment. Importantly, missense polymorphisms in human HRG1 are defective in heme transport. Our results reveal HRG1 as the longsought heme transporter for heme-iron recycling in macrophages and suggest that genetic variations in HRG1 could be modifiers of human iron metabolism.
INTRODUCTION
In humans, terminal erythroid differentiation is the process by which the earliest morphologically recognizable erythroid precursor in the bone marrow, the proerythroblast, differentiates into a mature red blood cell (RBC) in the peripheral blood (Ji et al., 2011) . This transformation requires the coordinated maturation of the nucleus and cytoplasm that eventuates in fully hemoglobinized mature RBCs, devoid of a nucleus and all other organelles (Chasis and Mohandas, 2008; Mohandas and Chasis, 2010) . Defects in numerous pathways can disrupt this sequence of maturation, but none is as important as the synthesis of hemoglobin, which requires the stoichiometric assembly of four globin peptides (two a and two b chains) and four heme (iron-protoporphyrin IX) moieties. Fully one-third of the protein in an RBC is hemoglobin which contains more than a billion iron atoms in the form of heme (Knutson and Wessling-Resnick, 2003) . Consequently, it is not surprising that inherited or acquired defects in hemoglobin synthesis, including hemoglobinopathies, iron deficiency, and the anemia of inflammation, are among the most prevalent human afflictions.
Defects in the synthesis or metabolism of any one of the three components-globin, iron, or protoporphyrin IX-lead to ineffective erythropoiesis. While globin and porphyrin synthesis are the province of the RBC precursor itself, iron metabolism requires systemic homeostatic control that regulates iron absorption in the intestine, iron storage in the liver and macrophages, and erythroid uptake and utilization. Importantly, most of the $25 mg of iron required to synthesize the hemoglobin in over 360 billion RBCs each day (5 million per second) derives from recycling of heme-iron from aged RBCs catabolized by reticuloendothelial system (RES) macrophages (Bratosin et al., 1998) . At steady state, dietary heme and nonheme iron absorption contributes only 1-2 mg per day to the systemic iron economy (Andrews, 1999; Hentze et al., 2010) .
RBC recycling occurs by a process known as erythrophagocytosis (EP), which is accompanied by the enzymatic catabolism of RBC components within the macrophage phagolysosome, resulting in the breakdown of hemoglobin and the release of heme (Bratosin et al., 1998) . Several lines of evidence support a cellular model in which the degradation of heme occurs in the cytosol via the catalytic activity of the smooth endoplasmic reticulum-associated enzymes heme oxygenases 1 and 2 (HMOX1/2), producing iron, biliverdin, and carbon monoxide (Gottlieb et al., 2012; Yanatori et al., 2010; Yoshida and Sato, 1989) . The iron liberated from heme can be stored in ferritin (FTH1/FTL1) or transported out of the cell by the iron exporter ferroportin (FPN1) whose cell surface expression is controlled by the iron regulatory hormone hepcidin (HAMP1) (Weiss, 2009) . This model of EP necessitates the transport of heme from the lumen of the phagolysosome into the cytosol, although the identity of the hypothetical heme transporter on the phagolysosomal membrane has not been identified.
Notwithstanding the importance of their function to iron metabolism and erythropoiesis, identification and characterization of heme and other porphyrin transporters in mammals have proven to be difficult (Hamza and Dailey, 2012; Quigley et al., 2004; Severance et al., 2011) . This is in part due to a lack of genetic and molecular tools but is also a consequence of the promiscuity of proteins capable of transporting heme with low affinity, which has confounded functional cloning experiments Krishnamurthy et al., 2004 Krishnamurthy et al., , 2006 Qiu et al., 2007; Saison et al., 2012; Salojin et al., 2011; Shayeghi et al., 2005; Wang et al., 2012) . Furthermore, the lack of in vivo experimental validation or in vivo phenotypes of those proteins identified in vitro or solely on the basis of in vivo expression patterns has been misleading or provided ambiguous results.
We exploited C. elegans, a heme auxotroph, to identify HRG1-related heme transporters (Rajagopal et al., 2008) . Worms acquire heme from the environment and transport it throughout the organism, negating several of the variables that have historically confounded the mammalian heme transport field (Rao et al., 2005) . Depletion of hrg-1 in worms by RNAi leads to abnormal heme sensing and accumulation of heme analogs (Rajagopal et al., 2008) . Transient knockdown of zfhrg1 in zebrafish leads to profound erythropoietic defects, while ectopic expression of human HRG1 in murine erythroleukemia cells leads to enhanced ZnMP uptake. HRG1 is conserved in vertebrates, and human and worm proteins bind heme (Rajagopal et al., 2008; Yuan et al., 2012) . Furthermore, the strength of this interaction is low pH dependent, suggesting that it may function in an acidic microenvironment, such as the phagolysosome. Correspondingly, HRG1 localizes primarily to the endolysosome in nonpolarized cells. Here we show that the long-sought heme transporter for macrophage heme-iron recycling is the human homolog of C. elegans HRG1 and identify a polymorphism that may be a genetic modifier of heme metabolism in humans. Our studies in mice, zebrafish, yeast, and mammalian cell lines support this conclusion.
RESULTS

HRG1 Is Abundantly Expressed in Reticuloendothelial Macrophages
To identify the tissue distribution of HRG1, polyclonal antibodies were generated against the 18 amino acid cytoplasmic C terminus of human HRG1. Immunoblotting with the antisera detected an $15 kDa band corresponding to the predicted molecular weight of HRG1 monomers, in various human and mouse cell lines ( Figure 1A and see Figure S1A online). Knockdown of either human or mouse HRG1 by siRNA resulted in a significant reduction in HRG1 protein, indicating that the signal detected by immunoblotting was authentic (Figure 1B and Figure S1B) . Immunohistochemistry with HRG1 antibodies detected high levels of HRG1 in the macrophages of the spleen, liver, and bone marrow in wild-type 129SvEv/Tac mice and humans-tissues that constitute the reticuloendothelial macrophage system responsible for recycling the heme iron in effete RBCs ( Figures 1C and 1D and Figures S1C and S1D ). HRG1 was also detected as weak granular/vesicular staining within hepatocytes ( Figures 1C and 1D , right panels), consistent with the nearly ubiquitous expression of HRG1 mRNA and protein in different cell types and tissues (Rajagopal et al., 2008) .
Hrg1 Is Recruited to Phagolysosomal Membranes during Erythrophagocytosis
To ascertain the function of HRG1 in mammals, bone marrowderived macrophages (BMDMs) from mice were isolated and differentiated ex vivo. Consistent with the previously observed location of ectopic human HRG1::GFP in HEK293 cells, endogenous Hrg1 was localized primarily to the endolysosome in BMDM by immunofluorescence microscopy ( Figure 1E ). To simulate EP, we exposed BMDM to oxidized RBCs. Oxidation of RBCs exposes phosphatidylserine on the outer membrane leaflet, mimicking cellular senescence and enhancing susceptibility to phagocytosis by macrophages (Cambos and Scorza, 2011) . Strikingly, the phagolysosomal membranes of macrophages surrounding the RBCs were greatly enriched with Hrg1 ( Figure 1F ). Quantitation of the fluorescence signal intensity revealed that Hrg1 was recruited to the phagolysosomal membranes specifically during phagocytosis of RBCs, but not latex beads ( Figure 1G versus Figure 1H , and Figure 1I ). Additionally, no signal was detected in BMDM either under resting conditions or during phagocytosis using pre-immune serum ( Figures S1E and S1F ). The enhancement in Hrg1 immunofluorescence was derived from the BMDMs and not the engulfed RBCs, as mature RBCs do not express detectable Hrg1 ( Figure S1G ). Furthermore, recruitment of Hrg1 to the phagolysosomal membranes was not an indirect consequence of heme or iron, as BMDMs exposed to opsonized latex beads in the presence of either heme:arginate (20 mM) or iron (Fe:NTA, 200 mM) did not influence Hrg1 trafficking ( Figure S1H ). In resting BMDMs, a negligible portion of Hrg1 overlapped with the lysosomal marker Lamp; however, during EP, Hrg1 and Lamp1 protein strongly colocalized on the phagolysosomal membrane ( Figure S1I ), supporting the notion that Hrg1 is specifically recruited to the phagolysosome during EP.
Hrg1 Is Regulated by Heme, Iron, and EP We next determined whether EP regulates Hrg1. BMDM exposed to RBCs showed greater abundance of Hrg1 mRNA and protein in a time-dependent manner (Figures 2A and 2B ). This regulation was also dose dependent, as increasing the ratio of RBCs to macrophages showed a proportional increase in Hrg1 levels ( Figures 2C and 2D ). To distinguish between the individual contributions of heme and iron on Hrg1 expression, EP was performed in the presence of the iron chelator deferoxamine (DFO). Exposure of BMDM to DFO only partially suppressed Hrg1 induction ( Figure 2E ). This time-and dose-dependent regulation of Hrg1 was reproducible by heme and iron ( Figures S2A-S2C) . Furthermore, other genes critical for heme-iron recycling, namely Hmox1, essential for heme degradation, and Fpn1, required for iron export, showed a similar responsiveness to EP, heme, and iron, although the magnitude of fold-change was different ( Figures S2D-S2G ) (Delaby et al., 2008) .
Although Hrg1 mRNA is upregulated in BMDMs grown in the presence of heme-depleted media and supplemented with 100 mM iron, 0.5 mM succinyl acetone, an inhibitor of endogenous heme synthesis, suppressed Hrg1 mRNA induction by iron ( Figure 2F ). This result suggests that Hrg1 is regulated indirectly by iron via de novo heme synthesis.
We have previously shown that noniron metalloporphyrins act as heme analogs and are transported by HRG1 proteins (Rajagopal et al., 2008; Rao et al., 2005) . To determine whether the effects of heme on Hrg1 expression could be reproduced by a metalloporphyrin, we exposed BMDM to zinc protoporphyrin IX (ZnPPIX). ZnPPIX is a physiologically relevant metalloporphyrin because its levels increase during iron-deficiency anemia (Labbé et al., 1999) . Moreover, ZnPPIX is nonmetabolizable and inhibits heme degradation by binding to HMOX enzymes (Labbé et al., 1999) . Hrg1 levels increased in a dose-dependent manner in BMDM that were exposed to ZnPPIX ( Figure 2G ). High concentrations of ZnPPIX, as expected, resulted in reduced ferritin levels, an indication that iron release from heme is attenuated due to inhibition of Hmox-dependent heme catabolism. These results affirm that iron via heme and noniron metalloporphyrins regulate Hrg1 in macrophages.
Hrg1 Is Regulated by Hemolysis In Vivo
To substantiate our in vitro cell biological studies in vivo, we injected mice with phenylhydrazine, which causes hemolytic anemia by damaging circulating erythrocytes, resulting predominantly in intravascular hemolysis (Itano et al., 1975 released hemoglobin and heme are cleared from the circulation by haptoglobin and hemopexin, respectively, resulting in a concomitant net increase in intracellular heme within macrophages of the RES. Phenylhydrazine-treated mice showed a dramatic increase in Hrg1 within the resident macrophages of the liver and spleen ( Figure 3A and Figure S3A ). These results were highly reproducible and comparable when mice were injected with either oxidized RBCs or heme arginate to mimic a transient increase in intravascular heme (Figures 3B and 3C, Figures S3B and S3C) .
To determine whether Hrg1 is regulated in a genetic animal model of anemia due to a defect in heme synthesis, we analyzed Hrg1 in tissues from mice with erythropoietic porphyria. The Fech m1Pas mouse carries a recessive hypomorphic allele and expresses approximately 5% of wild-type ferrochelatase activity, resulting in a mild hemolytic anemia, associated with a vast excess of protoporphyrin IX production and tissue protoporphyrin IX accumulation (Davies et al., 2005) . We found that Hrg1 was strikingly elevated in liver macrophages of homozygous Fech m1Pas mice ( Figure 3D ), indicating that Hrg1 is induced in vivo in conditions of protoporphyrin IX accumulation and chronic hemolysis.
Hrg1 Mediates Heme Transport from the Phagolysosome during Erythrophagocytosis
We hypothesized that Hrg1 recruitment to the phagolysosomal membranes may be connected to its function as a heme transporter. If this hypothesis were correct, then Hrg1 must transport heme from the lumen into the cytosol based on its membrane orientation and topology (Yuan et al., 2012) , and downstream markers that are induced during EP would be dependent on Hrg1 function (Delaby et al., 2008; Marro et al., 2010) . To substantiate this proposition, we knocked down Hrg1 by siRNA. Because Hmox1 and Fpn1 mRNA inductions signify heme and iron availability during EP, we assessed the response of these markers to Hrg1 siRNA. siRNA treatment resulted in greater than 75% depletion in Hrg1 mRNA and protein levels in BMDM grown in heme-depleted culture media ( Figures 4A and 4B, Figure S4A) . Strikingly, Hrg1 knockdown resulted in a significant attenuation of Hmox1 and Fpn1 mRNA induction during EP ( Figures 4C and 4D, Figures S4B and S4C ). This suppression prevailed in the presence of the iron chelator DFO, confirming Figure S4D for Hrg1 immunoblot. See also Figure S4 .
that both heme and iron regulate Hrg1. Importantly, knockdown of Hrg1 during EP resulted in a concomitant reduction in ferritin accumulation ( Figure 4E and Figure S4D) . These results unequivocally demonstrate that Hrg1 is essential for heme transport from the phagolysosome during EP and is genetically upstream from Hmox1, Fpn1, and ferritin, known markers of heme-iron recycling.
Missense Polymorphisms in Human HRG1 Result in Defective Heme Transport To determine whether genetic variations in human HRG1 may be modifiers of iron metabolism, we searched the NHLBI Exome Sequencing Project (ESP 5400 and ESP 6500SI) and found three missense variants in HRG1-G73S (frequency in population, 0.0309%), S82L (0.0309%), and W115C (0.0279%). These three variants were present in European Americans (EAs) but not in African Americans (AAs). However, the ESP database can be biased because they selectively remove extremely rare variants and samples that have first-to third-degree kinship to ensure sampling of unrelated DNA. To identify additional missense variants, we sequenced coding regions and intron-exon boundaries in DNA obtained from patient cohorts with unexplained microcytic anemia. A single sequence variant in HRG1/SLC48A1 was identified (c. 107C > T, P36L) in an AA proband who was also a compound heterozygote for mutations in TMPRSS6 and thus had iron refractory iron deficiency anemia (IRIDA) (Finberg et al., 2008) ; the patient's unaffected mother was also a carrier for the P36L variant and a TMPRSS6 allele. Furthermore, we sequenced Coriell Control DNA panels of 50 AA and 50 EA and found two additional AA samples that were carriers for the P36L variant. This polymorphism was not identified in EA.
Amino acid sequence alignments revealed that only tryptophan 115 and proline 36 are highly conserved in vertebrate HRG1 ( Figure S5A ). Topology modeling of vertebrate HRG1 predicts W115 to be located in the center of the fourth transmembrane domain (TMD) while P36 lies within a stretch of five amino acids (YRQPG) in the first exoplasmic (E1) loop between TMD 1 and TMD 2 ( Figure 5A ). The presence of a central turninducing proline within short luminal helical hairpins between TMD segments is a key topogenic determinant of membrane proteins (Monné et al., 1999) .
To assess the significance of each of the amino acid substitution, we exploited growth assays in yeast. Saccharomyces cerevisiae hem1D strains are unable to grow in aerobic conditions due to a genetic defect in the heme biosynthesis enzyme d-aminolevulinic acid synthase. However, the hem1D growth defect can be rescued by supplementation of the growth medium with either d-aminolevulinic acid or low amounts of exogenous heme (0.25 mM) plus HRG1 expression (Yuan et al., 2012) . Neither G73S nor S82L had any effect on the growth of hem1D yeast, while W115C showed a modest effect on growth (Figure S5B) . However, the P36L variant showed a severe reduction in yeast growth compared to wild-type HRG1 at both 0.25 and 1 mM heme.
To further explore the functional consequence of the P36 substitution in HRG1, we generated single-copy integrants of HRG1 in hem1D yeast which expressed equivalent levels of wild-type and P36L proteins ( Figure S5C ). The P36L variant was unable to rescue the growth of hem1D, even in the presence of 10 mM heme, whereas wild-type HRG1 restored growth of yeast with as little as 0.25 mM heme ( Figure 5B ). Unlike wildtype HRG1 (p < 0.0001), P36L did not alter intracellular heme levels (p > 0.05), as b-galactosidase activity remained unchanged in yeast expressing the CYC1::lacZ promoter-reporter fusion ( Figure 5C ). b-galactosidase activity reflects the availability of regulatory pools of cytoplasmic heme to activate CYC1 expression (Yuan et al., 2012) .
To evaluate the significance of the P36L substitution in vivo, we utilized a vertebrate animal model. We have previously reported that transient knockdown of zfhrg1a with antisense morpholino (MO2) in zebrafish embryos results in a severe erythropoietic defect that can be rescued by coinjection with C. elegans HRG1 (Rajagopal et al., 2008) . Coinjection of wildtype zfhrg1a with MO2 significantly rescued the morphant anemia phenotype (p < 0.01), but the P34L variant, the polymorphic ortholog of the human P36L variant, was unable to rescue the hematological defects (p > 0.05; Figure 5D , and Figure S5D ).
A Hemoprotein Reporter in Mammalian Cells Interrogates Heme Availability and P36L Functionality
The results from yeast and zebrafish suggest that the P36L variant is defective in heme transport. To corroborate this finding during EP in mouse BMDM, we created a hemoprotein reporter which can be used in a robust assay to directly evaluate intracellular heme levels. We chose the horseradish peroxidase (HRP) enzyme because it contains a heme cofactor, and as such, perturbations in cellular heme levels result in a concomitant change in HRP activity that is easily measured by in-gel assays, in situ histochemistry, or plate assays (Veitch, 2004) . To confine HRP to the secretory compartment, we incorporated a Golgi targeting sequence from galactosyltransferase into the amino terminus of HRP (Bard et al., 2006) . HRP activity in HEK293 cell lines was directly proportional to both exogenous and endogenously synthesized heme ( Figure 5E ). Succinyl acetone significantly attenuated HRP activity, while supplementation of heme to the growth medium greatly enhanced HRP activity (Figure 5E ). Importantly, HRP activity was directly dependent on heme because iron chelation by DFO did not attenuate HRP activity ( Figure 5E ). This result was reproducible in BMDM, as HRP activity was enhanced in a dose-dependent manner in response to heme supplementation in the growth medium ( Figure 5F ).
To test whether the P36L polymorphism alters heme transport, we transduced BMDM with adenoviral vectors driving the expression of HRG1, Golgi-HRP, or both ( Figures S5E and S5F ). As expected, the activity of HRP was significantly enhanced in the presence of either heme supplementation or EP in cells that overexpressed wild-type HRG1 ( Figures 5G and 5H , p < 0.0001). Consistent with our studies in yeast and zebrafish, the P36L variant failed to activate HRP above vector controls under either condition (p > 0.05), suggesting that this variant is unable to function normally. Notably, this difference in function was not because of reduced expression or aberrant intracellular localization, as immunolocalization experiments revealed comparable levels and similar localization patterns of wild-type and P36L proteins in adenoviral transduced BMDM ( Figure S5G ). Altogether, our studies in yeast, zebrafish, and mouse macrophages provide compelling evidence that the P36L missense variant is a dysfunctional transporter.
DISCUSSION
The importance of iron recycling is emphasized by the fact that the majority of body iron required to produce new RBCs is acquired by recycling iron derived from heme contained within hemoglobin from senescent RBCs (Andrews, 1999) . Although several genes involved in iron recycling have been identified, including Nramp1 (Vidal et al., 1996) , Nramp2/DMT1 (Fleming et al., 1997; Gunshin et al., 1997) , heme oxygenase 1, and ferroportin 1 (Abboud and Haile, 2000; Donovan et al., 2000; McKie et al., 2000) , compelling cell biological evidence has supported the existence of a heme transporter on the macrophage phagolysosomal membranes, but none have been found to date. Studies have shown that proteolytic degradation of hemoglobin in the phagolysosome results in the release of heme, which is subsequently degraded by heme oxygenase enzymes to yield biliverdin, carbon monoxide, and iron (Maines, 1997) . The catabolism of heme during EP (Marro et al., 2010) is mediated primarily by the induction of Hmox-1, an enzyme tethered to the endoplasmic reticulum membranes with the active site facing the cytosol (Gottlieb et al., 2012) . This model dictates that heme must be transported from the phagolysosome into the cytosol for catabolism and iron release ( Figure 5I ). Evidence exists that cytosolic labile pools of heme increase following EP. For example, Delaby et al. (Delaby et al., 2008) have previously (C) The P36L polymorph is defective in heme transport in yeast. hem1D(6D) yeast strains stably expressing either pYes-DEST52 vector control, hHRG1-HA, or hHRG1 P36L-HA were cotransformed with pCYC1-LacZ and grown in 2% w/v raffinose SC (ÀHis, ÀTrp) medium for 12 hr, washed, and grown in 2% w/v raffinose SC (ÀHis, ÀTrp, + 0.4% w/v galactose) medium supplemented with 1 mM or 2.5 mM hemin. Galactosidase activity (Miller units) was measured in cell lysates. Statistical analysis is as follows: n = 3, vector versus hHRG1-HA p < 0.0001, vector versus P36L-HA p > 0.05; error bars represent SEM.
(D) The P34L variant of zebrafish hrg1a is unable to rescue the hematological defects associated with hrg1a MO2 (hrg1a MO2 + zf hrg1a P34L versus hrg1a MO2, p > 0.05) compared to wild-type zfhrg1a (hrg1a MO2 + zf hrg1a versus hrg1a MO2, p < 0.01). Zebrafish embryos injected with hrg1a MO2 (2.7 ng/ embryo) exhibit a hematological defect (hrg1a MO2 versus uninjected, p < 0.001; see Figure S8B ). Rescue experiments were performed by coinjecting hrg1a MO2 with 120 pg/embryo of hrg1a mRNA or 120 pg/embryo of hrg1a P34L mRNA in one to two cell-stage embryos. Following O-dianisidine staining at 48 hpf (hours postfertilization), the numbers of affected embryos showing erythroid defects were counted; $150 embryos were analyzed per morpholino treatment. The graph shows the percentage of morphants (erythroid defect) and wild-type (no erythroid defect) embryos. Error bars represent the SEM.
(E) Golgi HRP activity is dependent on heme. HEK293 cells were grown in HD media (À) and pretreated with 100 mM DFO or 0.5 mM succinyl acetone (SA) where indicated. Following transfection with a construct expressing either vector control or Golgi-HRP, cells were exposed to 2 mM heme:arginate for 24 hr prior to harvesting. Golgi-HRP activity from lysates was assessed using on-blot chemiluminescence following SDS-PAGE. HRP protein was detected on a separate immunoblot using a rabbit a-HRP antibody. Actin is shown as a loading control.
(F) Dose response of HRP activity in BMDM transduced with adenovirus expressing Golgi-HRP in the presence of the indicated concentrations of heme. Inset represents data for 0-5 mM heme in enlarged format.
(G and H) Golgi-HRP activity in BMDM treated with 0.5 mM heme:arginate (G) or fed RBCs at a 1:1 RBC:BMDM ratio (H). BMDM were cotransduced with adenovirus expressing Golgi HRP and either pShuttle-CMV vector, hHRG1-HA, or hHRG1 P36L-HA (see Figures S5E and S5F ). Cell lysates were assessed for peroxidase activity (mU/ml). Values were normalized for total protein levels of corresponding lysates. Statistical analysis is as follows: HRP assay heme-treated samples, n = 9, vector versus hHRG1-HA p < 0.0001, vector versus P36L-HA p > 0.05; EP-treated samples, n = 9, vector versus hHRG1-HA p < 0.0001, vector versus P36L-HA p > 0.05; error bars represent the SEM (C, G, and H), values with different letter labels are significantly different (p < 0.05).
(I) Proposed model for HRG1-mediated heme transport in macrophages. Following phagocytosis of a senescent RBC by a macrophage cell, the RBC is sequestered in the phagolysosomal compartment and degraded via the activity of various enzymes, yielding the release of heme. During EP, HRG1 traffics from the endolysosomal compartment to the phagolysosomal membrane, where it functions to transport heme into the cytosol. Heme may be delivered to three separate pathways: (1) degradation by the HMOX1/2 enzymes, resulting in the release of iron, which may be exported back into the circulation via ferroportin (FPN1) or stored into ferritin (FTN); (2) incorporation in toto into hemoproteins; or (3) export via FLVCR. See also Figure S5 .
demonstrated that the transcription of Hmox1 and Fpn1 is specifically regulated by heme following EP in BMDMs. Additionally, Hmox1 À/À mice (Gottlieb et al., 2012) have little or no resident splenic and liver macrophages, possibly because of cytotoxic heme accumulation following EP (Kovtunovych et al., 2010) . We hypothesized that the human homolog of C. elegans HRG1 might be the phagolysosomal heme transporter based on the following rationale. First, both worm and human proteins bind and transport heme (Rajagopal et al., 2008) . Second, HRG1 homologs have low primary amino acid sequence identity ($20%) but retain overall topological conservation and strategically placed heme-binding residues (Yuan et al., 2012) . Third, worm and human HRG1 proteins colocalize with LAMP1 and the small GTPases Rab7 and Rab11 in HEK293 cells (Rajagopal et al., 2008) , markers known to contribute to the mature phagolysosome (Desjardins et al., 1994; Tjelle et al., 2000; Vieira et al., 2003) . Fourth, hemoglobinized RBCs are specified but cannot be maintained when hrg1 is knocked down in zebrafish. Lastly, ectopic expression of HRG1 in Friend mouse erythroleukemia cells shows enhanced uptake of ZnMP, a fluorescent heme analog (Rajagopal et al., 2008) . To test our hypothesis, we assessed the role of HRG1 in the RES during EP. We find that Hrg1 is abundantly expressed in the macrophages of the RES and localizes to the phagolysosomal membranes-a tissue and location highly relevant to heme-iron recycling, and consistent with the topological orientation of Hrg1 for heme transport from the lumen into the cytosol. These cell-biological studies are further supported by the concomitant increase in Hrg1 mRNA and protein during EP, which parallels the regulation of Hmox1 and Fpn1 (Delaby et al., 2005 (Delaby et al., , 2008 .
Importantly, Hrg1 depletion by siRNA results in a reduction in the regulatory heme pools, as demonstrated by the suppression of Hmox1, Fpn1, and ferritin inductions during EP (Delaby et al., 2008; Marro et al., 2010) . Consistent with this finding, ectopic expression of HRG1 in BMDM results in enhanced cellular heme availability during EP as measured by a significant increase in HRP enzymatic activity, a synthetic Golgi-targeted hemoprotein reporter. These results are recapitulated in vivo by inducing a transient increase in heme by phenylhydrazine injection, or treatment with heme or damaged RBCs in mice. All three treatments cause a dramatic increase in Hrg1 levels in resident macrophages of the liver, spleen, and bone marrow. In line with these results, a recent study showed that Hrg1 is upregulated in splenic macrophages derived from mice that have been chemically induced to mimic the anemia of inflammation and chronic disease (Prince et al., 2012) . The significance of the Hrg1 response to conditions of increased physiological demand on the RES is further emphasized in the hypomorphic Fech m1Pas mouse model of erythropoietic porphyria (Davies et al., 2005) . Although the exact mechanism(s) regulating Hrg1 during hemolytic anemia is not well understood, recent studies have identified binding sites for the heme-dependent transcriptional repressor BACH1 in the Hrg1, Hmox1, and Fpn1 gene promoters (Marro et al., 2010; Sun et al., 2002; Warnatz et al., 2011) . Taken together, these studies establish HRG1 as a critical component of the heme-iron recycling pathway in the RES ( Figure 5I) .
To address the possibility that inherited mutations in HRG1 could be associated with human disease, we screened DNA samples for rare variants and found a P36L variant in the AA population and three additional missense variants in EAs from the Exome Variant database. Results from our studies in yeast, zebrafish, and mouse macrophage show that the P36L variant is defective in heme transport. Previous studies in zebrafish have shown that HRG1 is critical for the maintenance of erythropoietic cells and the central nervous system (Rajagopal et al., 2008) . Modest reduction of hrg1 mRNA by antisense morpholinos in zebrafish embryos results in a hypomorphic morphant with only mild anemia, whereas a severe knockdown of hrg1 causes developmental defects including hydrocephalus and a curved body with shortened yolk tube (B. Paw and I.H., unpublished data). These variations in hrg1 phenotypes in zebrafish morphants may represent genetic alleles of HRG1 hypomorphs in the human population. We speculate that polymorphisms in HRG1 may be an important genetic determinant in inherited iron disorders in humans, including, for example, in the so-called ''African Iron Overload'' (AIO) or ''Bantu Siderosis,'' (Gordeuk et al., 2003) . Based on the results from our studies, we predict that Hrg1 knockout in mammals will reveal iron retention in macrophages and secondary systemic iron overload phenotypes. Screening for mutations in HRG1 in well-characterized cohorts of patients will provide further insight into the physiological significance of HRG1 in genetic disorders of iron metabolism (Adams et al., 2005; McLaren et al., 2003) . Given the striking similarities between heme utilization from senescent RBC in macrophages and heme transport from a diet rich in red meat in enterocytes (Severance et al., 2011; West and Oates, 2008) , it is conceivable that HRG1 may function as a heme transporter in the intestine.
EXPERIMENTAL PROCEDURES
Animal Strains, Cell Culture, and Reagents All animal experiments were approved by the University of Maryland Institutional Animal Care and Use Committee and by the Animal Care and Use Committee at Children's Hospital (Boston, MA). C57BL/6J or 129/SvEvTac mice were purchased from Jackson Laboratories or Taconic, respectively. Hrg1 protein expression in mice was induced by three methods. Mice were injected intraperitoneally with 3 mg/20 g weight phenylhydrazine hydrochloride (Aldrich) or equivalent volume PBS control. Furthermore, 1 mg total heme (Frontier Scientific) as heme:arginate (1 mM:10 mM [pH 7.5]) or arginine vehicle alone was injected retro-orbitally. Finally, whole blood was collected from C57BL/6J donor animals into Lithium-Heparin Microtainer tubes (Becton Dickinson), washed extensively with PBS, and treated with 0.2 mM CuSO 4 and 5 mM sodium-ascorbate (Sigma) for 60 min at 37 C. Cells were washed two times in excess 5 mM EDTA (PBS) and two times in excess PBS and brought up to 50% HCT in sterile PBS, and 200 ml damaged or untreated RBCs were injected retro-orbitally. Animals were euthanized 24 hr after injection and tissues harvested. Isolation and culture of bone marrow from the femur of C57BL/6 mice was carried out as described elsewhere (Marim et al., 2010) . Briefly, differentiation of fresh bone marrow cells was carried out in the presence of L929-conditioned media (LCM) as a source of granulocyte/macrophage colony-stimulating factor (Englen et al., 1995) . Differentiation media composition is as follows: RPMI 1640 (Invitrogen) supplemented with 30% LCM, 20% heat-inactivated fetal bovine serum (FBS, Atlanta Biologicals), 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine (Invitrogen). L-929 cells were purchased from the American Type Culture Collection (ATCC). For production of LCM, L-929 cells were grown in the presence of RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine for 30 days. Media was collected by sterile filtration and stored at À20
C for later use in BMDM differentiation and culture media. In all experiments described below, BMDMs were cultured in the presence of heme-depleted serum (HD) media as untreated control. HD media was prepared similarly to differentiation media with the exception of substituting 20% heme-depleted FBS for FBS. Heme depletion was achieved by treating FBS with ascorbic acid for $7-8 hr, followed by dialysis against PBS and filter sterilization. The depletion of heme from the serum was monitored by measurement of the optical absorbance at 405 nm. Depletion was considered successful when the absorbance of serum was reduced at least 50% following ascorbic acid treatment (Sassa and Nagai, 1996) . Unless otherwise noted, all chemicals and reagents were obtained from Sigma-Aldrich. Hemin and zinc protoporphyrin IX (ZnPPIX) were purchased from Frontier Scientific, Inc. Fresh 1 mM solutions of heme:arginate and ZnPPIX:arginate with 10 mM arginine were prepared by dilution in 0.2 M KOH/100% ethanol (1:1, v/v). Iron nitrolotriacetic acid (Fe:NTA) solution was prepared as a 1 mM stock with NTA (Sigma-Aldrich), and ferric chloride hexahydrate (molar ratio of 1:4). HRG1 antibody serum was produced in rabbit using the C-terminal 18 amino acid peptide sequence of human HRG1 as antigen (Epitomics, Inc.). Positive serum samples were selected based on high specificity to HRG1 as well as low unspecific background as tested by western blot analysis. Preimmune serum from the same rabbit was used as a negative control.
Statistical Analysis
Statistical significance was calculated by two-way analysis of variance with the Bonferroni multiple comparison test using Prism version 5.0 (GraphPad, San Diego, CA). Data values are presented as mean ± SEM. A p value < 0.05 was considered significant.
Additional material is available in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experimental Procedures and can be found with this article at http://dx.doi.org/10. 1016/j.cmet.2013.01.005.
